Aptose Biosciences Inc.
Home
About
Overview
Management Team
Board of Directors
Scientific Advisory Board
Product Pipeline
Overview
Tuspetinib for AML
Luxeptinib for B-cell Tumors
Luxeptinib for Myeloid Tumors
Posters & Presentations
Clinical Trials
Overview
Luxeptinib for CLL & NHL
Luxeptinib for AML
Tuspetinib for AML
Expanded Access
News
Press Releases
Presentations
Events
Investors
Overview
News & Events
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Join Us
Values & Culture
Perks & Benefits
Explore Careers
Contact
All SEC Filings
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
Financial Info
Overview
Financial Results
Income Statement
Cash Flow
Stock Data
NASDAQ: APTO
TSX: APS
Analyst Coverage
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
SEDAR
Governance
Overview
Board of Directors
Board Committees
Governance Documents
SEC Filings
Overview
All SEC Filings
Annual Reports
Quarterly Reports
Section 16 Filings
Filing Type:
View All
10-K
10-K/A
10-Q
20-F
20-F/A
25
25-NSE
3
4
4/A
40-F
424B2
424B3
424B4
424B5
6-K
6-K/A
8-A12B
8-K
8-K/A
CB
CERTAMX
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-3
F-3/A
F-X
NT 20-F
POS AM
PRE 14A
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SUPPL
UPLOAD
Year:
View All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
1998
1997
Date
Form
Description
PDF
XBRL
Pages
11/20/24
8-K
Current report filing
Documents
EX-99.1
5
11/19/24
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
11/19/24
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
1
11/14/24
SC 13G
Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions
7
11/12/24
10-Q
Quarterly report pursuant to Section 13 or 15(d)
Documents
EX-10.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
69
11/08/24
8-K
Current report filing
Documents
EX-99.1
7
10/31/24
CORRESP
A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
2
10/31/24
S-1/A
General form of registration statement for all companies including face-amount certificate companies
Documents
EX-4.2
EX-4.3
EX-4.4
EX-5.1
EX-5.2
EX-8.1
EX-10.23
EX-10.24
EX-23.1
EX-FILING FEES
150
10/04/24
8-K
Current report filing
2
09/06/24
8-K
Current report filing
2
Previous
1
2
3
4
5
6
7
8
9
10
…97
Next
Email Alerts
Contacts
RSS News Feed